Natilus and Palantir Announce Strategic Partnership to Accelerate Production of Sustainable Commercial Aircraft
SAN DIEGO, April 30, 2025 /PRNewswire/ -- Natilus, an aerospace manufacturer of blended-wing-body aircraft, today announced a strategic partnership with Palantir Technologies Inc. to advance the production of sustainable aircraft in the U.S. Through the collaboration, Natilus and Palantir are deploying an AI-based operating system to accelerate the development of innovative approaches to design, engineering and manufacturing and streamline Natilus's operations and strengthen its supply chain.
In an era of critically constrained access to aircraft components, market demand for cargo and passenger aircraft is outpacing domestic manufacturing capabilities. With the aviation industry challenged to operate more sustainably, cargo and passenger airlines are eager to pursue more technologically advanced approaches to deliver elevated yet economical fleet operations.
To address the market demand, Natilus is developing a family of blended-wing-body aircraft for commercial operations. With an advanced carbon fiber airframe design, Natilus's family of aircraft includes a regional blended-wing-body freighter KONA, and a 200-passenger aircraft, the HORIZON, which both offer major advantages in fuel consumption, carbon emissions, and payload capacity.
'The U.S. desperately needs a boost in aircraft manufacturing, and Natilus is operating at the forefront of sustainable aircraft manufacturing,' said Aleksey Matyushev, Co-Founder and CEO of Natilus. 'We made a commitment to build the first manufacturing facility for the world's most efficient commercial aircraft here in the U.S. Our success hinges on accelerating our production capabilities, and leveraging Palantir's AI-driven platform will allow us to transform our manufacturing operations to run more efficiently and meet customer demand for the cargo and passenger markets.'
Natilus is deploying Palantir Warp Speed for its operations, providing AI-driven data, analytics and modeling to drive real-time decision making. Through the collaboration, Natilus will initially focus on increasing supply chain resiliency and manufacturing efficiency, and further down the line, offering its cargo and passenger customers key insights to enable predictive maintenance, disruption recovery and capture real-time aircraft performance data for product optimization.
'Natilus is delivering the future of sustainable aircraft, and we are extremely proud of deploying software that supports the sustained competitive advantage of their blended-wing-body aircraft,' said Emily Nguyen, Head of Industrials at Palantir. 'By providing the foundation on which Natilus will integrate all aspects of their aircraft design, engineering and manufacturing, Palantir is committed to helping Natilus build faster and strengthen the U.S.'s position in the global aviation landscape.'
About Natilus
Natilus is a San Diego-based company developing a family of hyper-efficient blended-wing-body (BWB) aircraft designed to transport people and cargo more sustainably and efficiently than ever before. Natilus's BWB aircraft unlock improved aviation economics by reducing fuel consumption by 30% while increasing payload capability by 40%. Founded in 2016, the Natilus team is comprised of innovators from General Atomics, Northrop Grumman, Skunkworks, SpaceX, and Piper Aircraft. Learn more at natilus.co.
View original content to download multimedia: https://www.prnewswire.com/news-releases/natilus-and-palantir-announce-strategic-partnership-to-accelerate-production-of-sustainable-commercial-aircraft-302441974.html
SOURCE Natilus
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate)Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)Abstract Number: 2907Presentation Number: 2113PDate: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Mobile: +86 13062747000 View original content to download multimedia: SOURCE Antengene Corporation Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
7 hours ago
- CNBC
CNBC Daily Open: A week when everything happens
Choose a comfortable seat and grab your popcorn. These five days will basically be the Olympics for market watchers: And looming over all those financial and macroeconomic events is U.S. President Donald Trump's August 1 deadline for his new tariffs. As Kim Forrest, founder at Bokeh Capital, said, "What isn't happening in this week?" Here's the ideal scenario for investors. The Magnificent Seven companies reporting earnings this week and the U.S. economy secure gold at their respective events. (The Fed is expected to keep rates unchanged — whether this qualifies the central bank for a medal is up for debate). Big trading partners of the U.S., such as South Korea and India, secure a deal with the White House and join the European Union and Japan at the podium, while Beijing extends its tariff suspension with Washington. If those events happen, U.S. stocks will probably have legs clear hurdle after hurdle — and the S&P 500 can continue topping record announces a trade agreement with the European Union. Most European goods, including cars, exported to the U.S. will face a 15% tariff, Trump said Sunday. The bloc also agreed to purchase $750 billion worth of U.S. energy, he added. The Fed is ready to start lowering rates, Trump said. On Friday, the U.S. president said Fed Chair Jerome Powell told him "the country is doing well," which Trump took to mean "he's going to start recommending lower rates." Futures markets disagree. Perfect week for the S&P 500. The broad-based index rose Friday to close at a high — its fifth record in a row last week. The Nasdaq Composite and Dow Jones Industrial Average also advanced. The Stoxx Europe 600 lost 0.29%. Palantir joins rank of top 20 most valuable U.S. companies. After rising more than 2% on Friday to hit a market cap of $375 billion, Palantir bumped Home Depot out of the list. The software provider has more than doubled in value this year. [PRO] Keep an eye on these overbought stocks. Using CNBC Pro's stock screener tool, the team has identified 18 stocks that might be trading at levels higher than their fair value, based on their 14-day relative strength index. Under Trump, Uncle Sam is becoming an active investor The Trump administration has taken direct stakes in companies on a scale rarely seen in the U.S. outside wartime or economic crisis, pushing a Republican Party that traditionally championed free-market capitalism to embrace state intervention in industries viewed as important for national security. More interventions could be on the horizon as the Trump administration develops a policy to support U.S. companies in strategic industries against state-backed competition from China.
Associated Press
8 hours ago
- Associated Press
China proposes global cooperation body on AI
SHANGHAI, July 27, 2025 /PRNewswire/ -- A news report from The Chinese government has proposed the establishment of a world AI cooperation organization as part of its efforts to bolster open, inclusive and equitable artificial intelligence development and governance globally. Premier Li Qiang announced the initiative when addressing the opening ceremony of the 2025 World AI Conference and High-Level Meeting on Global AI Governance in Shanghai. Li emphasized the need for collaborative approaches to global AI governance to ensure that intelligent technologies are developed for the good of all. More than 1,000 high-level representatives from upwards of 40 countries and international organizations attended the opening ceremony of the three-day event, themed 'Global Solidarity in the AI Era'. Li said that the risks and challenges brought by AI development, such as machine hallucinations, deep fakes and AI proliferation, have aroused widespread attention. There is an urgent need to further consolidate a societal consensus on how to achieve a balance between development and security in the AI sector, he said. Li said greater emphasis should be placed on collective governance to ensure that AI ultimately benefits humanity. Given that global AI governance appears fragmented, it is essential to enhance coordination and alignment among countries around the world to establish a framework and rules for global AI governance with a broad consensus, he added. Noting that China places great importance on global AI governance and actively participates in promoting multilateral and bilateral cooperation in this regard, the premier said the nation is willing to offer more Chinese solutions to the international community and contribute more Chinese wisdom to global AI governance. In 2023, China proposed the Global AI Governance Initiative to promote an open, inclusive and fair approach to the development and governance of AI technologies. Last year, China proposed the AI Capacity-Building Action Plan for Good and for All to bridge the AI and digital divides, and to ensure the Global South benefits equitably from AI development. China actively promotes open source development, and is willing to collaborate with countries around the world to promote progress in software and hardware technologies, intensify open source initiatives, and collectively propel AI development to higher levels, Li said. Also on July 26, the conference adopted the Global AI Governance Action Plan, which calls on all parties to work in solidarity to advance AI development and governance. For more information: View original content to download multimedia: SOURCE
